Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression

Blood

Volumn 109, Issue 12, 2007, Pages 5380-5389

  Crotti, Andrea ^a   Lusic, Marina ^b   Lupo, Rossella ^c   Lievens, Patricia M J ^d   Liboi, Elio ^d   Della Chiara, Giulia ^a   Tinelli, Marco ^e   Lazzarin, Adriano ^a,f   Patterson, Bruce K ^g   Giacca, Mauro ^b   Bovolenta, Chiara ^c   Poli, Guido ^a,f,h  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c MOLMED S P A   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Hospital of Lodi   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DIBIT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CD8 ANTIGEN; GAG PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RNA POLYMERASE II; SMALL INTERFERING RNA; STAT5 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; VIRION; VIRUS EXPRESSION;

EID: 34250023195     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-042556     Document Type: Article

References (79)

1. Fauci AS. HIV and AIDS: 20 years of science. Nat Med. 2003;9:839-843.
2. Stevenson M. HIV-1 pathogenesis. Nat Med. 2003;9:853-860.
3. Bovolenta C, Camorali L, Lorini AL, et al. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood. 1999;94: 4202-4209.
4. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67-83.
5. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900-911.
6. Bovolenta C, Camorali L, Mauri M, et al. Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals. Clin Immunol. 2001;99:75-81.
7. Moriggl R, Gouilleux-Gruart V, Jahne R, et al. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol. 1996;16:5691-5700.
8. Bovolenta C, Testolin L, Benussi L, Lievens PM, Liboi E. Positive selection of apoptosis-resistant cells correlates with activation of dominant-negative STAT5. J Biol Chem. 1998;273:20779-20784.
9. Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev. 1999;10:131-157.
10. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell. 1998;95: 595-604.
11. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity. 1997;6:235-244.
12. Schwartz C, Canonne-Hergaux F, Aunis D, Schaeffer E. Characterization of nuclear proteins that bind to the regulatory TGATTGGC motif in the human immunodeficiency virus type 1 long terminal repeat. Nucleic Acids Res. 1997;25: 1177-1184.
13. Sgarbanti M, Borsetti A, Moscufo N, et al. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med. 2002;195:1359-1370.
14. Verdin E. DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol. 1991;65: 6790-6799.
15. Verdin E, Becker N, Bex F, Droogmans L, Burny A. Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1990;87:4874-4878.
16. Van Lint C, Burny A, Verdin E. The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites. J Virol. 1991;65:7066-7072.
17. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol. 1997;71:6113-6127.
18. Bovolenta C, Lorini AL, Mantelli B, et al. A selective defect of IFN-gamma- but not of IFN-alpha-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-gamma against HIV-1. J Immunol. 1999;162:323-330.
19. Alfano M, Poli G. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol. 2005;42:161-182.
20. Selliah N, Zhang M, DeSimone D, et al. The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology. 2006;344:283-291.
21. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest. 2005;115:128-137.
22. Ducrey-Rundquist O, Guyader M, Trono D. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol. 2002;76:9103-9111.
23. Ariyoshi K, Nosaka T, Yamada K, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000;275:24407-24413.
24. Yamada K, Ariyoshi K, Onishi M, et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol. 2000;71:46-54.
25. Vallanti G, Lupo R, Federico M, Mavilio F, Bovolenta C. T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner. Mol Ther. 2005;12:697-706.
26. Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. Embo J. 2003;22:6550-6561.
27. Al-Harthi L, Voris J, Patterson BK, et al. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med. 2004;5:55-65.
28. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989;86:2365-2368.
29. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity. 1995;2:587-596.
30. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science. 1988;241:1673-1675.
31. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238:800-802.
32. Yang X, Chen Y, Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF- kappaB. J Biol Chem. 1999;274: 27981-27988.
33. Watanabe S, Murakami T, Nakamura T, Morimoto C, Arai K. Human GM-CSF induces HIV-1 LTR by multiple signalling pathways. Biochimie. 2002;84: 633-642.
34. Kinter AL, Biswas P, Alfano M, et al. Interleukin-6 and glucocorticoids synergistically induce human immunodeficiency virus type-1 expression in chronically infected U1 cells by a long terminal repeat independent post-transcriptional mechanism. Mol Med. 2001;7:668-678.
35. Rizzi C, Crippa MP, Jeeninga RE, et al. Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1. J Immunol. 2006;176:999-1006.
36. Masters J, Hinek AA, Uddin S, et al. Poxvirus infection rapidly activates tyrosine kinase signal transduction. J Biol Chem. 2001;276:48371-48375.
37. Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol. 2000;165:5097-5104.
38. Kimura A, Naka T, Muta T, et al. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci U S A. 2005;102:17089-17094.
39. Selliah N, Zhang M, Desimone D, et al. The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology. 2006;344:283-291.
40. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986;234: 1563-1566.
41. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
42. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102:223-231.
43. Alfano M, Veglia F, Poli G. Role of peripheral blood mononuclear cell subsets of seronegative donors in HIV replication: suppression by CD8+ and CD16+ cells and enhancement by CD14+ monocytes. AIDS Res Hum Retroviruses. 1999; 15:489-491.
44. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol. 1996;16:6141-6148.
45. Azam M, Lee C, Strehlow I, Schindler C. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity. 1997;6:691-701.
46. Xia Z, Sait SN, Baer MR, et al. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res. 2001;25:473-482.
47. Mitchell TJ, Whittaker SJ, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res. 2003;63:9048-9054.
48. Barash I. Stat5 in the mammary gland: Controlling normal development and cancer. J Cell Physiol. 2006;209:305-313.
49. Meyer J, Jucker M, Ostertag W, Stocking C. Carboxyl-truncated STAT5beta is generated by a nucleus-associated serine protease in early hematopoietic progenitors. Blood. 1998;91:1901-1908.
50. Lee C, Piazza F, Brutsaert S, et al. Characterization of the Stat5 protease. J Biol Chem. 1999; 274:26767-26775.
51. Xia Z, Salzler RR, Kunz DP, et al. A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 2001;61:1747-1753.
52. Piazza F, Valens J, Lagasse E, Schindler C. Myeloid differentiation of FdCP1 cells is dependent on Stat5 processing. Blood. 2000;96:1358-1365.
53. Lehtonen A, Matikainen S, Miettinen M, Julkunen I. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol. 2002; 71:511-519.
54. Epling-Burnette PK, Garcia R, Bai F, et al. Carboxy-terminal truncated STAT5 is induced by interleukin-2 and GM-CSF in human neutrophils. Cell Immunol. 2002;217:1-11.
55. Wang D, Moriggl R, Stravopodis D, et al. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. Embo J. 2000;19:392-399.
56. Folks T, Powell DM, Lightfoote MM, Benn S, Martin MA, Fauci AS. Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science. 1986;231:600-602.
57. Ahmed M, Dusanter-Fourt I, Dugray A, et al. BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5. Leuk Lymphoma. 2001;42:445-455.
58. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature. 1996;384:529-534.
59. Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell. 1998;93:665-671.
60. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med. 1998;188:83-91.
61. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med. 1999;189:1735-1746.
62. Mui AL, Wakao H, Harada N, O'Farrell AM, Miyajima A. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol. 1995;57:799-803.
63. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido- 2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989;169:933-951.
64. Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol. 1998;72:7642-7647.
65. Kandanearatchi A, Zuckerman M, Smith M, Vyakarnam A, Everall IP. Granulocyte-macrophage colony-stimulating factor enhances viral load in human brain tissue: amelioration with stavudine. AIDS. 2002;16:413-420.
66. Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, Takemori T. Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. AIDS Res Hum Retroviruses. 1995;11:1031-1038.
67. Kedzierska K, Maerz A, Warby T, et al. Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages. AIDS. 2000;14:1739-1748.
68. Komuro I, Yokota Y, Yasuda S, Iwamoto A, Kagawa KS. CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection. J Exp Med. 2003;198:443-453.
69. Lokuta MA, McDowell MA, Paulnock DM. Identification of an additional isoform of STAT5 expressed in immature macrophages. J Immunol. 1998;161:1594-1597.
70. Folks T, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLV- III/LAV. J Immunol. 1986;136:4049-4053.
71. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med. 1995;332:567-575.
72. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
73. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis. 2000; 182:428-434.
74. Tambussi G, Ghezzi S, Nozza S, et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL) - 2 in antiviral drug - experienced human immunodeficiency virus - infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy. J Infect Dis. 2001;183:1476-1484.
75. Fagard C, Le Braz M, Gunthard H, et al. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. AIDS. 2003;17:1487-1492.
76. Brown PA, Angel JB. Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. J Immune Based Ther Vaccines. 2005;3:3.
77. Brites C, Gilbert MJ, Pedral-Sampaio D, et al. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS. J Infect Dis. 2000;182:1531-1535.
78. Jacobson JM, Lederman MM, Spritzler J, et al. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003;188: 1804-1814.
79. Teck R, Ascurra O, Gomani P, et al. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis. 2005;9:258-262.